assessing total tumor burden to plan appropriate treatment and to assess response to treatment. Through this short cases series, we aim to define the clinical indications for PET/CT in neoplastic plexopathy secondary to metastatic breast carcinoma.
INTRODUCTION
Brachial plexopathy a form of peripheral neuropathy causes pain, sensory loss, weakness, and loss of tendon reflexes in C5-T1 segmental distribution. The most common cause of nontraumatic plexopathy involving the brachial plexus is metastatic disease, most frequently seen from recurrent carcinoma breast. [1] Metastases carcinoma breast causing brachial plexopathy is a severely disabling disease and fortunately rare with an incidence of 0.5% and is thought to occur through lymphatic spread. [2] Differentiation of neoplastic brachial plexopathy (NBP) from radiation-induced plexopathy (RBP) is clinically difficult and forms the major indication for imaging. Magnetic resonance imaging (MRI) with or without positron emission tomography/computed tomography (PET/CT) is the standard approach for evaluation of these sets of patients. In addition to supplementing the clinical diagnosis of plexopathy, imaging also aids in included slice thickness -2 mm, pitch -0.83, voltage -120 kV, FOV -600 mm, rotation time -0.5 s, automated mA, and image matrix -512 × 512. About 80 ml of low-osmolar nonionic intravenous contrast was administered in all eligible patients at a rate of 1.8 ml/s, and scan delay was 50 s. PET/CT results were validated against clinical/magnetic resonance (MR) findings and clinical follow-up.
RESULTS
Our case series included 11 female patients mean age of patients was 60 years (range 48-72), and mean duration of onset of symptoms was 6 years postsurgery (range 3-11 years). Baseline PET/CT was positive for neoplastic plexopathy in 9 patients with evidence of distal metastasis in 5 patients. PET/CT was negative for disease in the axilla in 2 patients and discordant with positive MR findings, these were diagnosed as RBP. Follow-up PET/CT was available in 6 patients and showed progressive disease in 5, partial response in 1, and complete metabolic response in 1 patient.
DISCUSSION P o s i t r o n e m i s s i o n t o m o g r a p h y / c o m p u t e d tomography as an alternative/adjunct to magnetic resonance imaging for diagnosis
MRI is modality of choice for diagnosis of brachial plexopathy and preferred to other imaging modalities for characterization of brachial plexopathy due to its multiplanar capabilities, superior soft-tissue contrast, and absence of any ionizing radiation. However, it does have some limitations. These include poor image quality that may be attributed to motion artifacts and in-homogenous fat suppression in the shoulder region, routine contraindications such as claustrophobia, metallic implants, and deranged renal function (precluding the use of gadolinium contrast). [3] PET/CT can offer complimentary information to MR in diagnosis of NBP, can be used in situations where MR findings are equivocal or when MRI is contraindicated. [4] PET/CT in NBP shows intense focal/linear uptake along the course of involved nerves with or without FDG avid lymph nodes in axilla/supraclavicular region [5] [ Figure 1 ]. The complementary information provided by PET and MR separately in characterizing recurrent axillary and supraclavicular breast cancer makes NBP a good fit to the growing list of indications for PET/MR.
P o s i t r o n e m i s s i o n t o m o g r a p h y / c o m p u t e d tomography to differentiate neoplastic radiation plexopathy from radiation-induced plexopathy
Major clinical dilemma in follow-up breast cancer patients presenting with ipsilateral upper limb pain and/or sensorimotor weakness is to differentiate NBP due to tumor relapse from RBP since the treatment options differ for these entities. Clinical features suggestive of NBP include severe, relentless limb pain (most common symptom), muscle weakness, rapid progression, evidence of metastases elsewhere, and evidence of soft-tissue mass involving the branches of brachial plexus on imaging or biopsy. RBP is a rare slowly progressive neuropathy similar to NBP. Features that favor RBP are predominant paresthesia rather than pain, preferential involvement of upper trunk or C5-6 portion of plexus, history of radiotherapy dose exceeding 60 Gy, and myokymia on needle examination. [6] Clinical examination and electromyography cannot always differentiate RBP and NBP, and imaging evaluation is usually necessary. [7, 8] PET/CT is particularly useful in the clinical dilemma of differentiating RBP from NBP, where MR findings may be indeterminate. Since the pathophysiology of the RBP is chronic fibrosis, increased FDG uptake is less likely. On MRI, radiation fibrosis shows diffuse thickening and minimal or no enhancement along the brachial plexus. These usually display low signal intensity on both T1-and T2-weighted images although T2 hyperintensity and contrast enhancement in RBP is not uncommon [9] [ Figure 2 ]. Hence, MRI cannot always readily differentiate RBP from NBP. [10] PET/CT in RBP shows low-grade/minimal, diffuse FDG uptake in the enhancing/nonenhancing fibrotic tissue in axilla/ supraclavicular region [ Figure 3 ]. In fact, PET/CT appears to be the most appropriate imaging modality to differentiate tumor recurrence from RBP as recommended by the American College of Radiology. [11] 
P o s i t r o n e m i s s i o n t o m o g r a p h y / c o m p u t e d tomography to assessing the total disease burden and response to treatment
PET/CT appears to be most beneficial in carcinoma breast when evaluating subsets of patients with suspected locoregional recurrence and alters treatment decisions in up to 40% of patients by identifying clinical occult distant metastasis. [12] In our series, PET/CT identified distant metastasis in 36% (n = 4) of patients at the time of presentation of plexopathy, thereby altering treatment strategies and prognosis [ Figure 4 ]. The most frequent sites for distant metastasis in our series at presentation were the skeleton at baseline and the lung and brain on follow-up imaging.
Response assessment to chemotherapy in carcinoma breast is challenging with only clinical evaluation alone. Morphological imaging has its limitations in diagnostic assessment of sites such as operated bed or sites that received radiotherapy. Numerous studies have shown PET/CT superior to conventional imaging in response evaluation in carcinoma breast. [13] Most patients in our series (45%) with NBP on FDG PET/CT, with or without distant metastasis showed progressive disease after chemotherapy, thereby revealing the treatment refractory nature of this debilitating disease. PET/CT here can be useful for early identification of subsets of patients who will respond and the ones who will not benefit from an intended chemotherapy regimen [ Figures 5-7 ].
CONCLUSION
With increasing use of FDG PET/CT in patients with breast cancer, suspected cases of NBP should be recognized as an appropriate indication for metabolic imaging as it influences treatment management. In these sets of patients, FDG PET/CT plays an important adjunctive role to MRI and can potentially be a one-stop shop for (i) diagnosing neoplastic plexopathy and differentiating it from RBP, (ii) identifying metastatic disease outside the axilla, and (iii) and for monitoring response to treatment. 
